Equities research analysts expect Bicycle Therapeutics plc (NASDAQ:BCYC – Get Rating) to post ($0.70) earnings per share for the current quarter, Zacks reports. Seven analysts have made estimates for Bicycle Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.79) and the highest estimate coming in at ($0.64). Bicycle Therapeutics reported earnings per share of ($0.73) in the same quarter last year, which would suggest a positive year over year growth rate of 4.1%. The company is scheduled to report its next quarterly earnings report on Monday, January 1st.
According to Zacks, analysts expect that Bicycle Therapeutics will report full year earnings of ($3.05) per share for the current financial year, with EPS estimates ranging from ($4.17) to ($2.52). For the next year, analysts forecast that the firm will post earnings of ($3.85) per share, with EPS estimates ranging from ($5.00) to ($2.99). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that cover Bicycle Therapeutics.
Bicycle Therapeutics (NASDAQ:BCYC – Get Rating) last announced its quarterly earnings data on Tuesday, March 1st. The company reported ($0.63) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.03). Bicycle Therapeutics had a negative return on equity of 33.36% and a negative net margin of 571.25%. The firm had revenue of $3.77 million for the quarter, compared to analyst estimates of $6.31 million.
Shares of NASDAQ:BCYC traded down $16.12 during trading on Wednesday, hitting $30.87. 114,479 shares of the stock were exchanged, compared to its average volume of 289,350. The company’s fifty day simple moving average is $44.99 and its 200-day simple moving average is $50.26. The company has a debt-to-equity ratio of 0.09, a quick ratio of 12.65 and a current ratio of 12.65. The company has a market capitalization of $913.72 million and a price-to-earnings ratio of -11.69. Bicycle Therapeutics has a 1-year low of $26.39 and a 1-year high of $62.08.
A number of large investors have recently added to or reduced their stakes in the business. Shilanski & Associates Inc. bought a new position in shares of Bicycle Therapeutics during the fourth quarter worth approximately $314,000. Personal CFO Solutions LLC increased its stake in shares of Bicycle Therapeutics by 3.7% during the third quarter. Personal CFO Solutions LLC now owns 7,558 shares of the company’s stock worth $314,000 after purchasing an additional 273 shares during the period. HighMark Wealth Management LLC increased its stake in shares of Bicycle Therapeutics by 590.9% during the fourth quarter. HighMark Wealth Management LLC now owns 4,325 shares of the company’s stock worth $263,000 after purchasing an additional 3,699 shares during the period. State of New Jersey Common Pension Fund D bought a new position in shares of Bicycle Therapeutics during the third quarter worth approximately $203,000. Finally, Jump Financial LLC bought a new position in shares of Bicycle Therapeutics during the third quarter worth approximately $715,000. Hedge funds and other institutional investors own 54.69% of the company’s stock.
About Bicycle Therapeutics (Get Rating)
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.
- Get a free copy of the StockNews.com research report on Bicycle Therapeutics (BCYC)
- 3 Undervalued Stocks The Insiders Are Buying
- The Market For Gamestop Is Near A Turning Point
- PayPal Stock is Still Ready for Bargain Hunting
- It’s Personal: 3 Personal Care Stocks to Own in Volatile Markets
- Conagra Stock Has More Room to Grow
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.